Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzi Lizhong Wan is a traditional Chinese medicine (TCM) formula produced by Liaoning Jindan Pharmaceutical. It is an approved marketed product in China, primarily indicated for warming the middle jiao (spleen and stomach), dispelling cold, and tonifying qi. The formula is traditionally used to treat spleen-stomach deficiency-cold syndrome, which presents as abdominal cold pain, vomiting, diarrhea, and cold extremities. The preparation typically contains *Aconiti Lateralis Radix Praeparata* (Fuzi), *Zingiberis Rhizoma* (Ganjiang), *Codonopsis Radix* (Dangshen), *Atractylodis Macrocephalae Rhizoma* (Baizhu), and *Glycyrrhizae Radix et Rhizoma* (Gancao).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fuzi lizhong wan.